Albert Brandon
Family Medicine · Manchester, TNNPI 1376570424
Payments from drug & device makers
Across 122 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$335
- Novo Nordisk$271
- Astellas Pharma US Inc$226
- AstraZeneca$177
- Johnson & Johnson$131
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$88
- plus $714 from 19 others
What the payments were for
- Food & beverage$1,943100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $335 |
| Novo Nordisk | 19 | $271 |
| Astellas Pharma US Inc | 14 | $226 |
| AstraZeneca | 7 | $177 |
| Johnson & Johnson | 13 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $88 |
| Novartis | 6 | $85 |
| Amgen | 4 | $70 |
| Bayer | 3 | $67 |
| Eisai Inc. | 4 | $61 |
| Merck | 4 | $58 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Boehringer Ingelheim | 2 | $41 |
| Dexcom, Inc. | 2 | $40 |
| GSK | 3 | $40 |
| Lilly USA, LLC | 2 | $36 |
| Pfizer | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $26 |
| Abbott | 2 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$1,943 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 201 | $59,017 |
| TradjentaLinagliptin | 53 | $13,923 |
| LinzessLinaclotide | 20 | $11,482 |
| Budesonide | 57 | $9,954 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 52 | $9,855 |
| FarxigaDapagliflozin Propanediol | 29 | $8,111 |
| Divalproex Sodium | 155 | $7,361 |
| JanuviaSitagliptin Phosphate | 24 | $7,238 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 127 | $6,681 |
| Aripiprazole | 48 | $6,673 |
| Cinacalcet Hcl | 11 | $6,625 |
| BrilintaTicagrelor | 28 | $6,560 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $5,190 |
| Duloxetine Hcl | 97 | $5,144 |
| Mirtazapine | 128 | $4,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $59,017201 claims |
| AstraZenecaFarxiga, Brilinta | $177 | $14,67157 claims |
| Boehringer IngelheimTradjenta | $41 | $13,92353 claims |
| AbbVieLinzess | $335 | $11,48220 claims |
| MerckJanuvia | $58 | $7,23824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Manchester
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.